Ogeda Seeks Financing After Successful Phase II For Non-Hormonal Menopause Drug
Ogeda's non-hormonal menopause therapy, fezolinetant, has produced positive results in Phase II – an important step for the small Belgian biotech as it looks for partners or investment from further afield.
You may also be interested in...
New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.